TrialCancer science2019

Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.

Tomonori Hirashima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.